mp.weixin.qq.com·· 6 hours agoPickScore94
HORIZON-Breast06 Phase 3: Trastuzumab Rezetecan Extends PFS in HER2-Low Advanced Breast Cancer
In brief
The phase 3 HORIZON-Breast06 study of Hengrui Medicine's trastuzumab rezetecan (SHR-A1811) extended progression-free survival in patients with HER2-low advanced breast cancer.
Why it matters
The study provides median PFS, HR and 95% CI for both the chemotherapy-naive and overall populations, enabling quantitative comparison of the ADC against chemotherapy.
Source: mp.weixin.qq.com · mp.weixin.qq.com